Faculty of Science, Engineering and Computing, Kingston University, London, UK.
Drug Des Devel Ther. 2021 Sep 21;15:3979-3984. doi: 10.2147/DDDT.S310418. eCollection 2021.
With the discovery of new antibiotics diminishing, optimising the administration of existing antibiotics such as amoxicillin-clavulanic acid has become a necessity. At present, the optimal approach for enhancing the effectiveness of time-dependent antibiotics involves extending the time at which antibiotic concentrations are maintained above the minimal inhibitory concentration by prolonging the infusion time. This pharmacodynamic rationale cannot be applied to co-amoxiclav because of poor stability at room temperature. The aim of this study was to establish the shelf-life of amoxicillin and clavulanic acid prepared in separate containers to determine the feasibility of 24-hr continuous infusion therapy.
A previously developed and validated stability-indicating HPLC method was used to establish the shelf-life of reconstituted amoxicillin and clavulanic acid when prepared in separate containers. Stability at clinical concentration was evaluated at three temperatures. To establish whether there were significant differences at the level of both active ingredients and temperature, results were analysed using analysis of covariance (ANCOVA) to assess differences between the attained slopes of regression.
Data obtained indicated amoxicillin and clavulanic acid stability superior to that previously proposed making it suitable for continuous infusion therapy. Analysis of regression slopes via ANCOVA showed that temperature significantly affected amoxicillin and clavulanic acid stability. Amoxicillin retained 90% of its initial concentration for 80.3 hrs when stored at 4°C, 24.8 hrs at 25°C and 9 hrs when incubated at 37°C. Clavulanic acid retained 90% of its initial concentration for 152 hrs when stored at 4°C, 26 hrs at 25°C and 6.4 hrs when incubated at 37°C.
Amoxicillin and clavulanic acid are suitable for administration via continuous infusion when prepared, stored, and administered in separate containers. Results obtained from this study aid in ameliorating current dosing regimens to optimise antibiotic efficacy; however, more in-depth amoxicillin and clavulanic acid y-site compatibility studies are warranted.
随着新抗生素的发现日益减少,优化现有抗生素(如阿莫西林-克拉维酸)的管理已成为当务之急。目前,通过延长抗生素浓度维持在最低抑菌浓度以上的时间来增强时间依赖性抗生素效果的最佳方法是延长输注时间。由于室温下稳定性差,这种药效学原理不适用于复方阿莫西林。本研究的目的是确定分别配制的阿莫西林和克拉维酸的有效期,以确定 24 小时连续输注治疗的可行性。
采用已建立和验证的稳定性指示高效液相色谱法,确定分别配制的复溶阿莫西林和克拉维酸的有效期。在三种温度下评估临床浓度下的稳定性。为了确定在两种活性成分和温度水平上是否存在显著差异,使用协方差分析(ANCOVA)分析结果,以评估达到的回归斜率之间的差异。
所获得的数据表明,阿莫西林和克拉维酸的稳定性优于先前提出的稳定性,使其适合连续输注治疗。通过 ANCOVA 分析回归斜率表明,温度对阿莫西林和克拉维酸的稳定性有显著影响。阿莫西林在 4°C 下储存时,初始浓度的 90%可保持 80.3 小时,在 25°C 下储存时为 24.8 小时,在 37°C 下孵育时为 9 小时。克拉维酸在 4°C 下储存时,初始浓度的 90%可保持 152 小时,在 25°C 下储存时为 26 小时,在 37°C 下孵育时为 6.4 小时。
当分别配制、储存和输注时,阿莫西林和克拉维酸适合通过连续输注给药。本研究结果有助于改善当前的给药方案,以优化抗生素的疗效;然而,需要进行更深入的阿莫西林和克拉维酸 Y 型相容性研究。